'Brands Don’t Die': Cipla Grabs Rights To Novartis’ Galvus In India

 
• By Anju Ghangurde

Novartis draws up perpetual license agreement with Cipla for its vildagliptin brand in India. Experts weigh in on some deal nuances and whether the DPP-4 inhibitor can deliver long-term value in an ultra-competitive segment.

Can Galvus Deliver Long-Term Value for Cipla? • Source: Shutterstock

More from Business

More from Scrip